The loss of Anika Therapeutics under GAAP for 9 months of 2020 amounted to $8.326 million, against a profit of $23.142 million in the previous year. Revenue increased 15.2% to $97.769 million, against $84.838 million in the previous year.
The loss of Anika Therapeutics under GAAP for 9 months of 2020 amounted to $8.326 million, against a profit of $23.142 million in the previous year. Revenue increased 15.2% to $97.769 million, against $84.838 million in the previous year. 
ir.anikatherapeutics.com
English (US) 